North America Diabetes Care Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

The North America Diabetes Care Devices Market was valued at USD 21 billion in 2024 and is estimated to grow at a CAGR of 12.4% to reach USD 66.8 billion by 2034.

The rising incidence of diabetes, particularly type 2 diabetes, in North America is a major driver for the diabetes care devices market. With over 30 million people living with diabetes in the U.S. alone, the demand for reliable glucose monitors, insulin pumps, and continuous glucose monitoring (CGM) systems is increasing. This growing patient population is fueling the need for more effective and accessible diabetes management tools.

Rising Adoption of Devices

The devices segment held a notable share in 2024, driven by technological advancements. Devices such as continuous glucose monitors (CGMs), insulin pumps, and smart glucose meters have transformed diabetes management by offering real-time monitoring and better control of blood sugar levels. CGMs have become a game-changer for people living with diabetes, providing them with continuous, non-invasive blood glucose tracking.

Homecare to Gain Traction

The home care segment generated significant revenues in 2024. With a growing preference for managing chronic conditions at home, the demand for home-use diabetes devices such as home glucose monitors, insulin pumps, and portable A1c analyzers has surged. The rise of telemedicine and remote patient monitoring is further accelerating this trend, as patients now have more flexibility in managing their diabetes without frequent visits to healthcare facilities.

U.S. to Emerge as a Lucrative Region

U.S. diabetes care devices market is poised to grow significantly through 2034, driven by a combination of high disease prevalence, technological advancements, and a growing focus on chronic disease management. With over 30 million Americans living with diabetes, the market has seen a shift from traditional blood glucose meters to more sophisticated technologies such as CGMs, smart insulin pens, and automated insulin delivery systems.

Major players in the North America diabetes care devices market are Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, Becton, Dickinson and Company, BIONIME, DarioHealth, Dexcom, Dr. Reddy’s Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, Insulet, LifeScan Inc., Medtronic, Nova Biomedical, Novo Nordisk, Platinum Equity Advisors, Sanofi, Sinocare, and Tandem Diabetes Care.

To strengthen their foothold in the North America diabetes care devices market, companies are adopting several key strategies. First, manufacturers are heavily investing in research and development (R&D) to innovate and create more accurate, user-friendly, and cost-effective devices. This is especially evident in the push toward personalized diabetes management with products like CGMs that provide real-time data synced to mobile apps. Strategic partnerships are also a critical part of the growth strategy. For example, companies are collaborating with insurance providers, healthcare networks, and technology firms to improve device accessibility and ensure that patients have more affordable options.

Comprehensive Market Analysis and Forecast

• Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
• Competitive landscape with Porter’s Five Forces and PESTEL analysis
• Market size, segmentation, and regional forecasts
• In-depth company profiles, business strategies, financial insights, and SWOT analysis

This product will be delivered within 2-4 business days.